Note 1 – Organization and Description of Business
Our Company
Amarantus Bioscience Holdings (“AMBS” or “The Company”) is a biotechnology holding company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through our subsidiaries. The Company’s new Hemp-focused business plan via wholly-owned subsidiary Hemp BioHealth, Inc. to focus on neurological applications for inhalable non-psychoactive cannabinoid products, and our biotechnology portfolio which consists of Engineered Skin Substitute (autologous full thickness skin grating), MANF (neurotrophic factor protein for ophthalmology and Parkinson’s), PhenoGuard (neurotrophic factor discovery platform), eltoprazine (serotonin agonist for CNS disorders, including Parkinson’s levodopa induced dyskinesia), TBIA (blood tests for cancers), LymPro Test (Alzheimer’s blood test), NuroPro (blood test for Parkinson’s) and Theralink (tumor biopsy phosphoprotein biomarker platform for cancer drug selection) are being developed by technology-focused subsidiaries. The subsidiary portfolio consists of wholly-owned subsidiaries and partially-owned subsidiaries:
Wholly-owned subsidiaries
(i)Cutanogen Corporation that is preparing to initiate a potentially pivotal clinical development program for the autologous, full thickness skin grafting program Engineered Skin Substitute (“ESS”) for the treatment of large, life-threatening pediatric severe burns, with significant additional potential applications in the treatment of critical care and cosmetic-related applications;
(ii)MANF Therapeutics, Inc. that is developing the pre-clinical stage protein drug candidate mesencephalic astrocyte-derived neurotrophic factor (“MANF”) for the treatment of vision loss associated with the rare genetic condition Wolfram’s Syndrome, as well as the treatment of other vision-related disorders such as retinitis pigmentosa, glaucoma and macular degeneration. Additionally, MANF has potential applications in the treatment of Parkinson’s disease, diabetes and several other conditions;
(iii)Trimeric Labs, Inc. that is further exploiting the neurotrophic factor discovery platform “PhenoGuard” from which MANF was discovered. Trimeric is seeking to discover additional neurotrophic factors from PhenoGuard as potential treatments for Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, ALS, and other neurological conditions;
(iv)Hemp BioHealth, Inc. that is seeking to develop inhalable non-psychoactive cannabinoid products for the smoking cessation and other CNS-related disorders;
Partially-owned subsidiaries
(v)15% ownership in Todos Medical Ltd. (based in Israel, NASDAQ: TOMD) that is developing the TBIA cancer blood testing platform focused on the early detection of breast cancer, colon cancer and lung cancer as well as the Alzheimer’s blood diagnostic LymPro Test® as a pre-symptomatic blood test for Alzheimer’s disease, as well as potentially for the early diagnosis of CTE;
(vi)50% ownership in Elto Pharma, Inc. that is preparing to initiate a Phase 2b clinical trial for the small molecule drug candidate eltoprazine for the treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID), with additional potential applications for the treatment of agitation in Alzheimer’s disease and adult attention deficit and hyperactivity disorder (adult ADHD);
(vii)32.4% common stock ownership in Avant Diagnostics, Inc. (OTCPK: AVDX) that is commercializing the phosphoprotein tumor analysis platform Theralink® to improve diagnosis and treatment response rates across all cancers.
- RegA Filing
Sept. 2019
https://sec.report/Document/0001213900-19-019...EdmZGxPYQ..
July 2019 PR
AMBS’ 50%-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer’s aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. Elto Pharma entered into an agreement to be acquired by specialty pharmaceutical company Coeptis Pharmaceutical, Inc. that is commercializing the FDA-approved Consensi in late 2019. Under the terms of the agreement, AMBS would own approximately 25% of the combined company post-acquisition.
https://www.globenewswire.com/news-release/20...atmen.html
In the Reg A filing there is no mention of a finalized deal with Coeptis. It just mentions Amarantus' 50% ownership of subsidiary Elto Pharma, Inc.
So there is a question of what the percentage will end up being. It may have restructured the deal.
Will have to wait and see.
To speak with certainty about any of this is foolish.
Broad strokes that will be updated as Gerald moves forward.
Much Aloha
Our Company
Amarantus Bioscience Holdings (“AMBS” or “The Company”) is a biotechnology holding company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through our subsidiaries. The Company’s new Hemp-focused business plan via wholly-owned subsidiary Hemp BioHealth, Inc. to focus on neurological applications for inhalable non-psychoactive cannabinoid products, and our biotechnology portfolio which consists of Engineered Skin Substitute (autologous full thickness skin grating), MANF (neurotrophic factor protein for ophthalmology and Parkinson’s), PhenoGuard (neurotrophic factor discovery platform), eltoprazine (serotonin agonist for CNS disorders, including Parkinson’s levodopa induced dyskinesia), TBIA (blood tests for cancers), LymPro Test (Alzheimer’s blood test), NuroPro (blood test for Parkinson’s) and Theralink (tumor biopsy phosphoprotein biomarker platform for cancer drug selection) are being developed by technology-focused subsidiaries. The subsidiary portfolio consists of wholly-owned subsidiaries and partially-owned subsidiaries:
Wholly-owned subsidiaries
(i)Cutanogen Corporation that is preparing to initiate a potentially pivotal clinical development program for the autologous, full thickness skin grafting program Engineered Skin Substitute (“ESS”) for the treatment of large, life-threatening pediatric severe burns, with significant additional potential applications in the treatment of critical care and cosmetic-related applications;
(ii)MANF Therapeutics, Inc. that is developing the pre-clinical stage protein drug candidate mesencephalic astrocyte-derived neurotrophic factor (“MANF”) for the treatment of vision loss associated with the rare genetic condition Wolfram’s Syndrome, as well as the treatment of other vision-related disorders such as retinitis pigmentosa, glaucoma and macular degeneration. Additionally, MANF has potential applications in the treatment of Parkinson’s disease, diabetes and several other conditions;
(iii)Trimeric Labs, Inc. that is further exploiting the neurotrophic factor discovery platform “PhenoGuard” from which MANF was discovered. Trimeric is seeking to discover additional neurotrophic factors from PhenoGuard as potential treatments for Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, ALS, and other neurological conditions;
(iv)Hemp BioHealth, Inc. that is seeking to develop inhalable non-psychoactive cannabinoid products for the smoking cessation and other CNS-related disorders;
Partially-owned subsidiaries
(v)15% ownership in Todos Medical Ltd. (based in Israel, NASDAQ: TOMD) that is developing the TBIA cancer blood testing platform focused on the early detection of breast cancer, colon cancer and lung cancer as well as the Alzheimer’s blood diagnostic LymPro Test® as a pre-symptomatic blood test for Alzheimer’s disease, as well as potentially for the early diagnosis of CTE;
(vi)50% ownership in Elto Pharma, Inc. that is preparing to initiate a Phase 2b clinical trial for the small molecule drug candidate eltoprazine for the treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID), with additional potential applications for the treatment of agitation in Alzheimer’s disease and adult attention deficit and hyperactivity disorder (adult ADHD);
(vii)32.4% common stock ownership in Avant Diagnostics, Inc. (OTCPK: AVDX) that is commercializing the phosphoprotein tumor analysis platform Theralink® to improve diagnosis and treatment response rates across all cancers.
- RegA Filing
Sept. 2019
https://sec.report/Document/0001213900-19-019...EdmZGxPYQ..
July 2019 PR
AMBS’ 50%-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer’s aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. Elto Pharma entered into an agreement to be acquired by specialty pharmaceutical company Coeptis Pharmaceutical, Inc. that is commercializing the FDA-approved Consensi in late 2019. Under the terms of the agreement, AMBS would own approximately 25% of the combined company post-acquisition.
https://www.globenewswire.com/news-release/20...atmen.html
In the Reg A filing there is no mention of a finalized deal with Coeptis. It just mentions Amarantus' 50% ownership of subsidiary Elto Pharma, Inc.
So there is a question of what the percentage will end up being. It may have restructured the deal.
Will have to wait and see.
To speak with certainty about any of this is foolish.
Broad strokes that will be updated as Gerald moves forward.
Much Aloha
6
